Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atricure (ATRC)
NASDAQ:ATRC
Holding ATRC?
Track your performance easily
ATRC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.94 - $42.99
Previous Close$35.74
Volume551.79K
Average Volume (3M)571.38K
Market Cap
$1.74B
Enterprise Value$1.67B
Total Cash (Recent Filing)$130.34M
Total Debt (Recent Filing)$61.87M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Feb 25, 2025EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding48,753,251
10 Day Avg. Volume455,961
30 Day Avg. Volume571,379
Standard Deviation0.13
R-Squared0.34
Alpha-0.00530
Financial Highlights & Ratios
Price to Book (P/B)3.78
Price to Sales (P/S)3.96
Price to Cash Flow (P/CF)22.10
P/FCF Ratio26.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.74
Enterprise Value/Gross Profit5.57
Enterprise Value/Ebitda-107.63
Forecast
1Y Price Target
$44.75Price Target Upside24.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Atricure News
PremiumCompany Announcements
AtriCure Reports Strong Growth in Q3 2024 Earnings
Bulls Say, Bears Say
Bulls Say
Financial PerformanceATRC reported Q3/24 revenue of $115.9M, beating Street estimates and showing a strong year-over-year growth of 17.9%.
Product InnovationPain management recorded its strongest quarter with $17.9M, a 36.3% increase driven by the successful launch of cryoSPHERE+.
Strategic InitiativesATRC's exclusive license agreement to add PFA to their portfolio highlights significant growth potential for the company's future.
Bears Say
Financial GuidanceThe company lowered full-year 2024 guidance by approximately $4 million due to the relative softness within its MIS Ablation and MIS Appendage Management segments.
Market DynamicsThe negative impacts to the business stemmed from Electrophysiologists shifting their time to new Pulse Field Ablation catheter devices.
Market PerformanceThe Minimally Invasive division came in just below consensus as market dynamics around the introduction of PFA continued.
---
Ownership Overview
3.17% Insiders
36.37% Mutual Funds
33.85% Other Institutional Investors
10.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATRC FAQ
What was Atricure’s price range in the past 12 months?
Atricure lowest stock price was $18.94 and its highest was $42.98 in the past 12 months.
What is Atricure’s market cap?
Currently, no data Available
When is Atricure’s upcoming earnings report date?
Atricure’s upcoming earnings report date is Feb 25, 2025 which is in 91 days.
How were Atricure’s earnings last quarter?
Atricure released its earnings results on Oct 29, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.025.
Is Atricure overvalued?
According to Wall Street analysts Atricure’s price is currently Undervalued.
Does Atricure pay dividends?
Atricure does not currently pay dividends.
What is Atricure’s EPS estimate?
Atricure’s EPS estimate is -$0.23.
How many shares outstanding does Atricure have?
Atricure has 48,753,250 shares outstanding.
What happened to Atricure’s price movement after its last earnings report?
Atricure reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 18.349%.
Which hedge fund is a major shareholder of Atricure?
Among the largest hedge funds holding Atricure’s share is Royce & Associates LLC. It holds Atricure’s shares valued at 2M.
---
Atricure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.75 (24.27% Upside)
$44.75 (24.27% Upside)
Blogger Sentiment
Bullish
ATRC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 28.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.4%
Last 30 Days ▼ 14.3%
Last 30 Days ▼ 14.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.50%
12-Months-Change
Fundamentals
Return on Equity
-8.39%
Trailing 12-Months
Asset Growth
2.46%
Trailing 12-Months
Company Description
Atricure
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
---
ATRC Company Deck
---
ATRC Earnings Call
Q3 2024
0:00 / 0:00
---
ATRC Stock 12 Month Forecast
Average Price Target
$44.75
▲(24.27% Upside)
Technical Analysis
Best Analysts Covering ATRC
1 Year
1 Year Success Rate
20/22 ratings generated profit
1 Year Average Return
+46.00%
reiterated a buy rating 28 days ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +46.00% per trade.
---